All In Biotech

Drug Trial Radar · NCT06049030

A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma

A Phase Ia/Ib Study of HS-10516 to Investigate the Safety, Tolerance, Pharmacokinetic and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Sep 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

190

Planned (sponsor's estimate)

Start

Sep 25, 2023

Primary completion

Sep 25, 2024

Study completion Sep 25, 2025

Sponsor

Sponsor type
Industry
First posted
Sep 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary efficacy of HS-10516 in ccRCC.

Conditions

  • Renal Cell Carcinoma

Interventions

  • HS-10516Drug

    Oral HIF-2α inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia: MTD/MAD of HS-10516Time frame: Approximately 2 months
  2. Phase Ib: Objective Response Rate (ORR) by Independent Review Committee (IRC)Time frame: Approximately 1 year

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.